Skip to main content
. 2019 Nov 28;50:421–432. doi: 10.1016/j.ebiom.2019.11.006

Fig 1.

Fig 1

Sub-study population, randomisation and analysis in treatment year 1 and 2. Numbers of subjects signing informed consent, randomised into placebo, BM32-low, BM32-high treatment during first treatment year and receiving placebo and BM32-low in the second year are displayed. For in- and exclusion criteria, please refer to Table S1. Numbers of subjects who discontinued and reasons are shown.